NCT07189910View on ClinicalTrials.gov

Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

November 1, 2027

Study Completion Date

December 31, 2027

Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
DRUG

Eltrombopag

Participants assigned to the observation group will be treated with eltrombopag oral suspension (EPAG-pfos).

OTHER

Placebo

Participants in the control group will receive a placebo at the same dose, instead of eltrombopag oral suspension (EPAG-pfos).

Trial Locations (1)

430022,

Wuhan Union Hospital, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER